Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.36 Million CAD | 13.55% |
| 2022 | 16.63 Million CAD | 87.81% |
| 2021 | 8.85 Million CAD | -52.32% |
| 2020 | 18.57 Million CAD | -38.22% |
| 2019 | 30.07 Million CAD | 66.62% |
| 2018 | 18.04 Million CAD | -6.01% |
| 2017 | 19.2 Million CAD | 169.81% |
| 2016 | 7.11 Million CAD | 29.05% |
| 2015 | 5.51 Million CAD | 33.21% |
| 2014 | 4.13 Million CAD | 33.7% |
| 2013 | 3.09 Million CAD | -39.67% |
| 2012 | 5.13 Million CAD | 4.24% |
| 2011 | 4.92 Million CAD | 43.96% |
| 2010 | 3.42 Million CAD | -42.69% |
| 2009 | 5.96 Million CAD | 10.77% |
| 2008 | 5.38 Million CAD | 40.34% |
| 2007 | 3.83 Million CAD | 41.07% |
| 2006 | 2.72 Million CAD | 47.88% |
| 2005 | 1.84 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 3.76 Million CAD | 7.6% |
| 2024 Q1 | 4.13 Million CAD | -28.18% |
| 2024 Q2 | 3.63 Million CAD | -11.96% |
| 2023 Q2 | 4.89 Million CAD | 20.81% |
| 2023 Q4 | 5.75 Million CAD | 37.25% |
| 2023 Q3 | 4.19 Million CAD | -14.34% |
| 2023 FY | 18.89 Million CAD | 13.55% |
| 2023 Q1 | 4.05 Million CAD | -24.39% |
| 2022 Q3 | 3.72 Million CAD | -10.59% |
| 2022 Q4 | 5.35 Million CAD | 43.82% |
| 2022 Q2 | 4.16 Million CAD | 22.98% |
| 2022 Q1 | 3.38 Million CAD | 269.43% |
| 2022 FY | 16.63 Million CAD | 87.81% |
| 2021 Q2 | 3.1 Million CAD | -19.16% |
| 2021 Q1 | 3.83 Million CAD | 1.2% |
| 2021 Q3 | 3.91 Million CAD | 26.16% |
| 2021 FY | 8.85 Million CAD | -52.32% |
| 2021 Q4 | -1.99 Million CAD | -151.07% |
| 2020 Q4 | 3.79 Million CAD | 50.23% |
| 2020 FY | 18.57 Million CAD | -38.22% |
| 2020 Q2 | 6.47 Million CAD | 11.93% |
| 2020 Q1 | 5.78 Million CAD | -19.87% |
| 2020 Q3 | 2.52 Million CAD | -61.0% |
| 2019 Q3 | 7.31 Million CAD | -21.81% |
| 2019 Q2 | 9.35 Million CAD | 51.55% |
| 2019 Q1 | 6.17 Million CAD | 25.8% |
| 2019 FY | 30.07 Million CAD | 66.62% |
| 2019 Q4 | 7.21 Million CAD | -1.35% |
| 2018 Q1 | 4.01 Million CAD | -42.52% |
| 2018 Q2 | 4.81 Million CAD | 19.87% |
| 2018 Q3 | 4.3 Million CAD | -10.5% |
| 2018 Q4 | 4.9 Million CAD | 13.94% |
| 2018 FY | 18.04 Million CAD | -6.01% |
| 2017 Q2 | 4.22 Million CAD | 7.88% |
| 2017 Q3 | 4.09 Million CAD | -3.05% |
| 2017 Q4 | 6.98 Million CAD | 70.47% |
| 2017 FY | 19.2 Million CAD | 169.81% |
| 2017 Q1 | 3.91 Million CAD | 55.42% |
| 2016 Q3 | 1.79 Million CAD | 19.4% |
| 2016 Q2 | 1.5 Million CAD | 15.56% |
| 2016 Q1 | 1.29 Million CAD | -34.78% |
| 2016 FY | 7.11 Million CAD | 29.05% |
| 2016 Q4 | 2.52 Million CAD | 40.61% |
| 2015 Q2 | 1.15 Million CAD | 9.02% |
| 2015 Q4 | 1.99 Million CAD | 53.46% |
| 2015 FY | 5.51 Million CAD | 33.21% |
| 2015 Q3 | 1.29 Million CAD | 12.0% |
| 2015 Q1 | 1.06 Million CAD | -17.55% |
| 2014 Q2 | 936.14 Thousand CAD | -5.76% |
| 2014 Q4 | 1.28 Million CAD | 40.12% |
| 2014 Q1 | 993.41 Thousand CAD | 67.24% |
| 2014 FY | 4.13 Million CAD | 33.7% |
| 2014 Q3 | 920.42 Thousand CAD | -1.68% |
| 2013 FY | 3.09 Million CAD | -39.67% |
| 2013 Q4 | 594.01 Thousand CAD | -14.42% |
| 2013 Q3 | 694.14 Thousand CAD | -12.06% |
| 2013 Q2 | 789.33 Thousand CAD | -22.52% |
| 2013 Q1 | 1.01 Million CAD | -34.81% |
| 2012 Q1 | 1.14 Million CAD | -25.2% |
| 2012 FY | 5.13 Million CAD | 4.24% |
| 2012 Q4 | 1.56 Million CAD | 19.85% |
| 2012 Q3 | 1.3 Million CAD | 16.86% |
| 2012 Q2 | 1.11 Million CAD | -2.97% |
| 2011 Q2 | 1.13 Million CAD | 20.39% |
| 2011 FY | 4.92 Million CAD | 43.96% |
| 2011 Q1 | 946.57 Thousand CAD | -21.54% |
| 2011 Q4 | 1.53 Million CAD | 18.26% |
| 2011 Q3 | 1.3 Million CAD | 14.09% |
| 2010 Q1 | 781.87 Thousand CAD | -67.4% |
| 2010 FY | 3.42 Million CAD | -42.69% |
| 2010 Q4 | 1.2 Million CAD | 61.59% |
| 2010 Q3 | 746.59 Thousand CAD | 8.93% |
| 2010 Q2 | 685.4 Thousand CAD | -12.34% |
| 2009 FY | 5.96 Million CAD | 10.77% |
| 2009 Q4 | 2.39 Million CAD | 152.31% |
| 2009 Q3 | 950.44 Thousand CAD | -35.05% |
| 2009 Q2 | 1.46 Million CAD | 26.52% |
| 2009 Q1 | 1.15 Million CAD | -54.39% |
| 2008 Q2 | 1.44 Million CAD | 14.41% |
| 2008 Q3 | 763.87 Thousand CAD | -47.01% |
| 2008 FY | 5.38 Million CAD | 40.34% |
| 2008 Q4 | 2.53 Million CAD | 231.95% |
| 2008 Q1 | 1.25 Million CAD | -6.28% |
| 2007 Q1 | 591.15 Thousand CAD | -33.33% |
| 2007 Q3 | 1.12 Million CAD | 44.88% |
| 2007 Q4 | 1.34 Million CAD | 19.35% |
| 2007 Q2 | 777.46 Thousand CAD | 31.52% |
| 2007 FY | 3.83 Million CAD | 41.07% |
| 2006 FY | 2.72 Million CAD | 47.88% |
| 2006 Q3 | 690.19 Thousand CAD | 10.63% |
| 2006 Q2 | 623.88 Thousand CAD | 19.79% |
| 2006 Q1 | 520.82 Thousand CAD | -45.9% |
| 2006 Q4 | 886.75 Thousand CAD | 28.48% |
| 2005 Q3 | 352.46 Thousand CAD | 1.78% |
| 2005 Q2 | 346.28 Thousand CAD | 93.39% |
| 2005 Q4 | 962.62 Thousand CAD | 173.11% |
| 2005 FY | 1.84 Million CAD | 0.0% |
| 2005 Q1 | 179.06 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 83.451% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -192.031% |
| SQZ Biotechnologies Company | 85.61 Million USD | 83.226% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 51.403% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 61.451% |
| Mesoblast Limited | 5.9 Million USD | -143.339% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -856.245% |
| Genus plc | 147.7 Million USD | 90.276% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -63.589% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -970.545% |
| Marizyme, Inc. | 19.23 Million USD | 25.354% |
| ContraFect Corporation | 56.88 Million USD | 74.755% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -72.225% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -225.763% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -871.213% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -392.479% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -414.695% |
| MultiCell Technologies, Inc. | 567.42 USD | -2530977.332% |
| Accustem Sciences Inc. | 3.74 Million USD | -283.348% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 83.29% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2599.787% |
| Q BioMed Inc. | 3.43 Million USD | -317.905% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 41.89% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3586.625% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -446.593% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1344.589% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 93.631% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -113.781% |
| Skye Bioscience, Inc. | 13.54 Million USD | -6.011% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -601.02% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 57547.356% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -184.842% |
| IMV Inc. | 37.7 Million USD | 61.914% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 10.296% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -682.621% |
| GB Sciences, Inc. | 1.42 Million USD | -911.035% |
| Alpha Cognition Inc. | 9.7 Million USD | -47.975% |
| HST Global, Inc. | 140.9 Thousand USD | -10092.424% |
| CSL Limited | 3.44 Billion USD | 99.584% |
| Halberd Corporation | 74.84 Thousand USD | -19089.545% |
| Enzolytics Inc. | 2.17 Million USD | -558.949% |
| Resverlogix Corp. | 12.71 Million USD | -12.979% |
| Affymax, Inc. | 39.38 Million USD | 63.536% |
| SYBLEU INC | 160.87 Thousand USD | -8827.273% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -293.399% |
| argenx SE | 1.53 Billion USD | 99.063% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 74.997% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1275.655% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -809.348% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -321.789% |
| AVAX Technologies, Inc. | 7.31 Million USD | -96.461% |
| Zenith Capital Corp. | 8.94 Million USD | -60.593% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.26% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -82339.808% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -484.928% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -8273.811% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 85.541% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -716.163% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -628.275% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -670.332% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -32.16% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -647.66% |
| BioStem Technologies, Inc. | 22.97 Million USD | 37.489% |
| ONE Bio Corp. | 6.44 Million USD | -122.875% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -7813.513% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -975.446% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1176.71% |
| Agentix Corp. | 1.37 Million USD | -946.967% |
| LadRx Corporation | 3.81 Million USD | -276.774% |
| Cell Source, Inc. | 4.32 Million USD | -232.039% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3356.694% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1455.136% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1455.136% |
| NovAccess Global Inc. | 2.46 Million USD | -482.214% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -497.182% |
| Itoco Inc. | 919.14 Thousand USD | -1462.525% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -238.849% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1183.453% |
| Kadimastem Ltd | 2.41 Million USD | -495.899% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -5387.357% |
| CytoDyn Inc. | 18.05 Million USD | 20.468% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -56961.619% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2489.837% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -6425.795% |
| Qrons Inc. | 643.67 Thousand USD | -2131.218% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -911.545% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -544.064% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2062.928% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -690.711% |
| International Stem Cell Corporation | 5.27 Million USD | -172.469% |
| Bioxytran, Inc. | 3.82 Million USD | -275.95% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -27182.092% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -70498.432% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 60.399% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -787.629% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1851.774% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -361.647% |
| Neutra Corp. | 243.82 Thousand USD | -5790.321% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 17.73% |
| PureTech Health plc | 144.59 Million USD | 90.068% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 29.908% |
| IXICO plc | 4.7 Million USD | -205.117% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -63.258% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 87.803% |
| CSL Limited | 3.89 Billion USD | 99.631% |
| Cellectis S.A. | 97.32 Million USD | 85.243% |